Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7952 results

Sort By:

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Study ID: NCT06328673
Start Date: 2024-03-01
End Date: 2026-03-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

160

Intervention / Treatment

DM919

Pembrolizumab

Sponsor

D2M Biotherapeutics Inc.

Source: clinicaltrials.gov

Share:
Add to list

Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

Study ID: NCT03422731
Start Date: 2018-02-15
End Date: 2025-11-06
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

74

Intervention / Treatment

Biospecimen Collection

Dual-Energy Computed Tomography

Fluorothymidine F-18

Laboratory Biomarker Analysis

Magnetic Resonance Imaging

Positron Emission Tomography

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

Study ID: NCT04623931
Start Date: 2020-01-30
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

40

Intervention / Treatment

Quality-of-Life Assessment

Administration questionnaire

Radiation Therapy

Temozolomide

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Study ID: NCT03746431
Start Date: 2019-01-17
End Date: 2026-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

253

Intervention / Treatment

[111In]-FPI-1547 Injection

[225Ac]-FPI-1434 Injection multi-dose

FPI-1175 Infusion

[225Ac]-FPI-1434 Injection single-dose

Sponsor

Fusion Pharmaceuticals Inc.

Source: clinicaltrials.gov

Share:
Add to list

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

Study ID: NCT02446431
Start Date: 2014-07
End Date: 2029-07
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

20

Intervention / Treatment

Infatuating

Cyclophosphamide

Valproic Acid

Tmsirolimus

Sponsor

Miller Children's & Women's Hospital Long Beach

Source: clinicaltrials.gov

Share:
Add to list

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Study ID: NCT04892173
Start Date: 2021-12-10
End Date: 2027-06-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

500

Intervention / Treatment

JNJ-90301900 (NBTXR3)

Cetuximab

Radiation Therapy

Sponsor

Johnson & Johnson Enterprise Innovation Inc.

Source: clinicaltrials.gov

Share:
Add to list

The INSPIRE-Lung Study

Study ID: NCT05824273
Start Date: 2023-08-02
End Date: 2027-07-30
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

500

Intervention / Treatment

Lungtalk

Non-tailored intervention - Standard of practice

Sponsor

Hackensack Meridian Health

Source: clinicaltrials.gov

Share:
Add to list

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Study ID: NCT03547973
Start Date: 2018-08-13
End Date: 2030-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

827

Intervention / Treatment

Sacituzumab Govitatan-Kzius

Pembrolizumab

Cisplatin

Avelumab

Zimberelimab

Carboplatin

Gemcitabine

Domvanalimab

Emportumab Vedotin

Sponsor

Gilead Sciences

Source: clinicaltrials.gov

Share:
Add to list

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Study ID: NCT06704191
Start Date: 2025-04-21
End Date: 2026-06-06
Study Type

Interventional

Study Phase

Phase2

No. of Participants

40

Intervention / Treatment

BCG Solution

Cystoscopy

Docetaxel

Gemcitabine

Home Health Encounter

Mitomycin

Administration questionnaire

Sponsor

Mayo Clinic

Source: clinicaltrials.gov

Share:
Add to list

Seleno-Lionin (SLM)-Axitinib-Pemmbrolizumabababababol.

Study ID: NCT05363631
Start Date: 2022-09-19
End Date: 2026-12-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

55

Intervention / Treatment

Selenomethionine (SLM)

Sarcasm

Pembrolizumab

Sponsor

Mohammed Milhem

Source: clinicaltrials.gov

Share:
Add to list